MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma

Torre, 2015, Global cancer statistics, 2012, CA. Cancer J. Clin., 65, 87, 10.3322/caac.21262 Villanueva, 2013, Medical therapies for hepatocellular carcinoma: a critical view of the evidence, Nat. Rev. Gastroenterol. Hepatol., 10, 34, 10.1038/nrgastro.2012.199 Singal, 1998, Doxorubicin-induced cardiomyopathy, N. Engl. J. Med., 339, 900, 10.1056/NEJM199809243391307 Carvalho, 2009, Doxorubicin: the good, the bad and the ugly effect, Curr. Med. Chem., 16, 3267, 10.2174/092986709788803312 Vilaseca, 1978, Doxorubicin for liver cancer, Lancet, 1, 1367, 10.1016/S0140-6736(78)92448-0 Bangham, 1965, Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol., 13, 238, 10.1016/S0022-2836(65)80093-6 Klibanov, 1991, Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target, Biochim. Biophys. Acta, 1062, 142, 10.1016/0005-2736(91)90385-L Tahover, 2015, Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes, Anticancer Drugs, 26, 241, 10.1097/CAD.0000000000000182 Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev., 65, 36, 10.1016/j.addr.2012.09.037 Immordino, 2006, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomedicine, 1, 297 Tsuchiya, 2006, MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer, J. Pharmacol. Sci., 101, 267, 10.1254/jphs.CPJ06013X Chen, 2010, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy, Mol. Ther., 18, 1650, 10.1038/mt.2010.136 Gong, 2015, Emerging role of microRNA in hepatocellular carcinoma (Review), Oncol. Lett., 9, 1027, 10.3892/ol.2014.2816 He, 2012, MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo, Oncogene, 31, 3357, 10.1038/onc.2011.500 Liu, 2010, MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties, Biochem. Biophys. Res. Commun., 394, 623, 10.1016/j.bbrc.2010.03.036 Chang, 2012, miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions, Gastroenterology, 143, 177, 10.1053/j.gastro.2012.04.009 Yan, 2014, The emerging role of miR-375 in cancer, Int. J. Cancer, 135, 1011, 10.1002/ijc.28563 Tao, 2015, Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer, Oncotarget, 6, 6977, 10.18632/oncotarget.3166 Yoo, 2010, Molecular mechanism of chemoresistance by astrocyte elevated gene-1, Cancer Res., 70, 3249, 10.1158/0008-5472.CAN-09-4009 Yang, 2014, Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo, Theranostics, 4, 1096, 10.7150/thno.9423 Gandhi, 2014, Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances, J. Control Release, 194, 238, 10.1016/j.jconrel.2014.09.001 Wang, 2016, AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer, Onco Targets Ther., 9, 2385 Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145, 10.1038/nrd1632 Creixell, 2012, Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance, Nano Today, 7, 367, 10.1016/j.nantod.2012.06.013 Gillet, 2010, Mechanisms of multidrug resistance in cancer, Methods Mol. Biol., 596, 47, 10.1007/978-1-60761-416-6_4 Ding, 2016, An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9, Oncotarget, 7, 14405, 10.18632/oncotarget.7360